FindTrial
Sign In

ctDNA analysis

GENETIC9 trials

Sponsors

First People's Hospital of Hangzhou, The Christie NHS Foundation Trust, Nantes University Hospital, Centre Hospitalier Departemental Vendee, Hospices Civils de Lyon

Conditions

Adenocarcinoma of LungEGFR WildtypeGliomaMelanomaMetastatic Non-small Cell Lung CancerNon-Small-Cell Lung Cancer MetastaticNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage III

Phase 2

CAcTUS - Circulating Tumour DNA Guided Switch
NCT03808441
The Christie NHS Foundation TrustMelanoma
Start: 2019-05-02End: 2024-05-02Updated: 2023-08-25
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
Active, not recruitingNCT03865511
Nantes University HospitalNon-small Cell Lung Cancer
Start: 2019-04-09End: 2025-01-31Updated: 2024-02-28

Unknown Phase

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
CompletedNCT02418234
First People's Hospital of HangzhouNon-Small-Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage III
Start: 2015-03-31End: 2017-11-30Updated: 2018-03-12
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
CompletedNCT02623257
First People's Hospital of HangzhouNon-Small-Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage III
Start: 2016-01-31End: 2017-12-31Updated: 2018-02-13
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
NCT02946216
First People's Hospital of HangzhouAdenocarcinoma of Lung, EGFR Wildtype, Non-Small-Cell Lung Cancer Metastatic +1
Start: 2016-11-30End: 2018-11-30Target: 200Updated: 2016-10-27
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
CompletedNCT03926260
Centre Hospitalier Departemental VendeeMetastatic Non-small Cell Lung Cancer
Start: 2019-06-27End: 2022-05-23Updated: 2025-12-04
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
RecruitingNCT04931732
Hospices Civils de LyonGlioma
Start: 2021-11-04End: 2026-11-30Target: 150Updated: 2023-10-11
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
RecruitingNCT05853198
Azienda Ospedaliera Universitaria Integrata VeronaPDAC - Pancreatic Ductal Adenocarcinoma
Start: 2022-12-29End: 2026-05-31Target: 165Updated: 2023-05-10
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
RecruitingNCT05916755
Vall d'Hebron Institute of OncologyTriple Negative Breast Cancer
Start: 2023-01-13End: 2029-12-31Target: 100Updated: 2023-06-23

Related Papers

CAcTUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.
Journal of Clinical Oncology2021-05-2011 citations
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
2019-10-0120 citations
ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting.
2018-07-0111 citations